Novel markers for the evaluation of patients with suspected ischemic heart disease
At present, for the evaluation of patients with suspected acute coronary syndromes (ACS), currently available cardiac biomarkers depend on the presence of myocyte necrosis or left ventricular dysfunction in order to be diagnostic. With a better understanding of the pathophysiology that underlies the ACS has come a wide variety of candidate cardiac biomarkers, whose ability to detect the pathophysiologic processes involved in ACS may represent a step forward for the practicing clinician. Included among these novel biomarkers are markers of myocardial ischemia in the absence of necrosis (ischemia modified albumin and free fatty acids), markers of plaque inflammation and/or instability (myeloperoxidase, pregnancy-associated placental protein-A, whole blood choline, lipoprotein-associated phospholipase A2), as well as markers of platelet activity (soluble CD40 ligand). The potential role of these novel markers in the evaluation of patients with suspected ACS will be reviewed. Copyright © 2006 by Lippincott Williams & Wilkins.
Volume / Issue
Start / End Page
Electronic International Standard Serial Number (EISSN)
International Standard Serial Number (ISSN)
Digital Object Identifier (DOI)